Clinical trials: Severe Knee Osteoarthritis
Osteoarthritis (OA) of the Knee
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
- Trial name
- NCT06865079
- Testing
- TPX-100 200mg, Once weekly for 4 weeks, PBS
- Where
- 33 sites in United States
- Volunteers
- 270 people
- Sponsor
- OrthoTrophix, Inc
Chronic Low Back Pain, Osteoarthritis
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the efficacy of fasinumab in relieving Chronic low back pain (CLBP) as compared to placebo in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and…
- Trial name
- FACT CLBP 1 (NCT03285646)
- Testing
- Fasinumab
- Where
- 56 sites in United States
- Volunteers
- 63 people
- Sponsor
- Regeneron Pharmaceuticals
Knee Osteoarthritis
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
This phase 2 study is a placebo-controlled, double-blind, parallel group study of four concentrations of SM04690 (0.03, 0.07, 0.15, and 0.23 mg per 2 mL injection) injected intraarticularly (IA) into the target knee joint of…
- Trial name
- NCT03122860
- Testing
- SM04690
- Where
- 74 sites in United States
- Volunteers
- 700 people
- Sponsor
- Biosplice Therapeutics, Inc.
Pain, Nausea
A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain ("flare") associated with…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT02462850
- Testing
- CL-108
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Charleston Laboratories, Inc
Moderate to Severe Osteoarthritis
Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)
The purpose of this study is to find the optimal dose of SM04690 that can be safely given by intra-articular injection into the target knee joint of subjects with moderate to severe osteoarthritis.
- Trial name
- NCT02095548
- Testing
- SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- Biosplice Therapeutics, Inc.
Severe Knee Pain, Severe Knee Disability
Zimmer POLAR Persona - TKA (EMEA Study)
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona knee implants used in primary total knee arthroplasty. The assessment will include: 1.
- Conditions
- Severe Knee Pain, Severe Knee Disability, Osteoarthritis, Rheumatoid Arthritis
- Trial name
- NCT02337244
- Testing
- Zimmer Persona Total Knee System
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 777 people
- Sponsor
- Zimmer, GmbH
Osteo Arthritis Knee
Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.
- Trial name
- NCT04750252
- Testing
- StroMel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Akan Biosciences, LLC
Knee Osteoarthritis
Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)
This phase 3 study was a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic…
- Trial name
- NCT05603754
- Testing
- Lorecivivint
- Where
- 44 sites in United States
- Volunteers
- 499 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis
Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement
The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint.
- Trial name
- NCT00454298
- Testing
- AGG-523 (Aggrecanase Inhibitor)
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteoarthritis, Knee
An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee
The purpose of this study is to collect information regarding the long-term (6 and 12 months) safety of Tramadol HCl Once-A-Day(OAD) 300 mg.
- Trial name
- NCT00833911
- Testing
- Tramadol Once A Day
- Volunteers
- 392 people
- Sponsor
- Labopharm Inc.
Knee Osteoarthritis
Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee
This study will test efficacy and safety of AAE581 compared to placebo in limiting cartilage loss in patients with painful knee osteoarthritis which is confirmed by X-ray
- Trial name
- NCT00371670
- Testing
- balicatib (AAE581)
- Where
- 2 sites in United States, Germany
- Volunteers
- 223 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis
An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis
This long-term extension study is designed to monitor the long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously injected in the target knee joints of subjects with moderately to severely…
- Trial name
- NCT02951026
- Testing
- Not applicable (no therapy is administered as part of this study)
- Where
- 62 sites in United States
- Volunteers
- 703 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.
- Trial name
- NCT00394563
- Testing
- RN624 (PF-04383119)
- Where
- 48 sites in United States
- Volunteers
- 450 people
- Sponsor
- Pfizer
Osteoarthritis, Knee, Osteoarthritis, Hip
To Assess the Patients' Ability to Self-Administer Fasinumab
The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical…
- Trial name
- FACT DEVICE (NCT03491904)
- Testing
- Fasinumab AI, Fasinumab PFS
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- Regeneron Pharmaceuticals
Knee Osteoarthritis
A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee
A study to assess safety, tolerability and clinical effects of single and repeat dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
- Trial name
- NCT04229225
- Testing
- UBX0101
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Unity Biotechnology, Inc.
Osteoarthritis of Knee
Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee
To compare flavocoxid with naproxen for patients with moderate to severe osteoarthritis of the knee.
- Trial name
- NCT00790985
- Testing
- flavocoxid, Naproxen
- Volunteers
- 223 people
- Sponsor
- Primus Pharmaceuticals
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP
Knee Osteoarthritis
Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis…
- Trial name
- STRIDES-1 (NCT04385303)
- Testing
- Lorecivivint
- Where
- 76 sites in United States
- Volunteers
- 496 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis, Knee
A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis
The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint…
- Trial name
- NCT04875754
- Testing
- ICM-203
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- ICM Biotech Australia Pty Ltd.
Osteoarthitis, Chronic Pain
Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis
The purpose of this study was to examine a low and high dose of tapentadol extended release tablet taken orally twice a day to reduce pain in subjects suffering from chronic moderate to severe pain due to osteoarthritis of the…
- Conditions
- Osteoarthitis, Chronic Pain, Knee Pain
- Trial name
- NCT00745069
- Testing
- tapentadol HCl
- Volunteers
- 670 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.